FEMY vs PATH
Femasys Inc (FEMY) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Femasys Inc (FEMY) is a medical instruments & supplies company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported FEMY revenue for 2024-12-31 was $1.6M. Net income was -$18.8M. Revenue was up 52.0% from 2023-12-31 to 2024-12-31. FEMY currently screens at market cap $925.2K.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
FEMY currently screens at market cap $925.2K. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the FEMY and PATH stock pages for the full models.
Not investment advice.